As the Ministry of Health, Labor and Welfare refrains from recommending the HPV (human papillomavirus) vaccine, it is estimated that the number of people suffering from cervical cancer will increase to about 1 and the number of deaths will increase to about 7,000. It was found by analysis by Asami Yagi, a specially appointed assistant professor at the Graduate School of Medicine, Osaka University, and Yutaka Ueda.
According to Osaka University, HPV has a type that sticks to the skin and a type that sticks to the mucous membrane, and when the type that sticks to the mucous membrane infects the cervix, it may progress to cervical cancer.Vaccination is effective for prevention, but the Ministry of Health, Labor and Welfare has refrained from actively recommending it since 2013 due to concerns about side effects, and the HPV vaccination rate for women born after 2000 has dropped sharply.
The research group of Assistant Professor Yagi et al. Predicted the relative risk of cervical cancer morbidity and mortality in females born after 2000, and estimated the increase in the number of cervical cancer morbidity and mortality in each year of birth.As a result, it was found that the number of future morbidity and deaths will increase by about 2000 and the number of deaths will increase by about 2003 among females born in 1-7,000 who exceeded the target age for regular vaccination while the vaccination rate was low.
The HPV vaccine can be expected to be effective by giving females who had not been vaccinated during the period when the Ministry of Health, Labor and Welfare withheld the recommendation the opportunity to inoculate.The estimated result of this increase in morbidity and deaths is that women who could have been prevented by vaccination did not receive vaccination, so the research group needs to resume vaccination recommendations as soon as possible. There is.
